Audience Discussion: Optimizing Clinical Trial Design & Navigating Regulatory Landscape for Wet AMD & Diabetic Eye Disease Therapies
Time: 8:45 am
day: Day One
Details:
- Part 1: Diabetic Eye Disease
- Part 2: Wet AMD
Moderated by: Michael Tolentino, Chief Innovation Officer, Aviceda Therapeutics
